Tradestie Institutional Equity Comparison Engine

AKRO vs RVMD โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

RVMD Overall Edge

RVMD Captures Institutional Edge (2โ€“1 Pillars ยท 1โ€“6 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Revolution Medicines, Inc. Common Stock (RVMD) driven by superior Momentum & Technical, Options & Structure while AKRO counters with relative strength in Growth & Margin. Fundamentally, AKRO trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus RVMD at N/M Forward P/E and -853.0% operating margin (-95.2% YoY). In options structure, AKRO sits in UNCLASSIFIED (30th %ile IV; Dealer Gamma Walls on Pro) against RVMD sits in CONSOLIDATION (26th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
AKRO N/M vs RVMD N/M Fwd P/E
Growth & Margin Winner AKRO
Op Margin 0.0% vs -853.0% ยท YoY +0.0% vs -95.2%
Momentum & Technical Winner RVMD
1Y +76.8% vs +128.6% ยท 52W Pos 90% vs 59%
Options & Structure Winner RVMD
UNCLASSIFIED (30th %ile IV) vs CONSOLIDATION (26th %ile IV)
AKRO NASDAQ
Akero Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$54.65
+0.32% 1D
Market Cap $4.5B
1M Return +1.37%
1Y Return +76.75%
Forward P/E N/M
Unified AI Score
60.0 / 100 BUY
Tech 55.0 Fund 52.0 Flow 50.0 Mom 50.0
RVMD NASDAQ
Revolution Medicines, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$161.20
+1.11% 1D
Market Cap $34.5B
1M Return -14.11%
1Y Return +128.56%
Forward P/E N/M
Unified AI Score
57.7 / 100 HOLD
Tech 62.0 Fund 64.0 Flow 69.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: AKRO +76.75% RVMD +128.56% Spread: +12.94 pp (RVMD Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
AKRO TTM Op. Margin: 0.0% RVMD TTM Op. Margin: -853.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AKRO vs RVMD. Trailing 12-month operating profitability (AKRO 0.0% vs RVMD -853.0%) and valuation multiples (AKRO N/M vs RVMD N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: AKRO (6) vs RVMD (1)
Institutional Metric AKRO RVMD Criterion Row Winner
Market Capitalization Scale $4.5B $34.5B Larger Scale RVMD
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% -95.2% Higher Growth AKRO
Operating Margin (TTM) Profitability 0.0% -853.0% Higher Margin AKRO
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -34.5% -93.6% Higher ROE AKRO
52-Week Range Position Momentum 90% ($21โ€“$58) 59% ($70โ€“$224) Stronger Trend AKRO
Beta / 30D Volatility Risk Regime 0.90ฮฒ ยท 2% Vol 1.35ฮฒ ยท 61% Vol Lower Realized Risk AKRO
Unified Institutional Score Composite Signal 60.0 / 100 (BUY) 57.7 / 100 (HOLD) Higher Composite AKRO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full AKRO vs RVMD Buy Guide
AKRO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 30th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live AKRO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
RVMD CONSOLIDATION
102d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 26th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live RVMD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither AKRO nor RVMD registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.